002788.SZ
鹭燕医药
SZSE · Healthcare · F 批发零售 · CN
CNY 10.56
−3.30%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 21.4B | 21.2B | 20.5B | 19.8B | 19.5B |
| Cost of Revenue | 19.9B | 19.7B | 18.9B | 18.3B | 17.9B |
| Gross Profit | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 7.0M | 6.5M | 5.8M | 5.5M | 4.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 346.4M | 342.4M | 321.2M | 309.3M | 298.8M |
| Selling & Marketing Expense | 513.7M | 506.9M | 467.9M | 441.7M | 432.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.1B | 1.1B | 1.1B | 1.0B | 998.0M |
| Cost and Expenses | 21.0B | 20.8B | 20.0B | 19.4B | 18.9B |
| Operating Income (EBIT) | 376.6M | 378.9M | 458.1M | 468.6M | 465.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 373.9M | 376.2M | 453.3M | 469.4M | 466.0M |
| Income Tax Expense | 98.6M | 97.2M | 105.6M | 104.9M | 115.0M |
| Bottom Line | |||||
| Net Income | 277.5M | 280.9M | 345.6M | 363.5M | 345.2M |
| Earnings from Cont. Ops | 275.3M | 279.0M | 347.7M | 364.5M | 351.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 277.5M | 280.9M | 345.6M | 363.5M | 345.2M |
| Per Share | |||||
| Basic EPS | CN¥0.71 | CN¥0.72 | CN¥0.89 | CN¥0.94 | CN¥0.89 |
| Diluted EPS | CN¥0.71 | — | — | — | — |
| Revenue Per Share | CN¥53.61 | CN¥54.46 | CN¥52.71 | CN¥51.32 | CN¥50.18 |
| Shares | |||||
| Basic Shares Outstanding | 399.6M | 390.1M | 388.4M | 386.7M | 387.8M |
| Diluted Shares Outstanding | 399.6M | 390.1M | 388.4M | 386.7M | 387.8M |
| Profitability Metrics | |||||
| EBITDA | — | 464.5M | 538.0M | 537.2M | 532.3M |
| D&A | — | 85.6M | 79.9M | 68.7M | 66.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026